Literature DB >> 2892452

Cetirizine effects on objective measures of daytime sleepiness and performance.

W F Seidel1, S Cohen, N G Bliwise, W C Dement.   

Abstract

Sixty healthy men and women with no sleep complaints, 21 to 45 years of age (mean age 28), were randomly assigned to one of five parallel groups that received one of the following: cetirizine 5 mg (n = 13), 10 mg (n = 13), or 20 mg (n = 11); hydroxyzine 25 mg (n = 12); or placebo (n = 11). After one adaptation night in the lab, the subjects' sleep patterns were recorded from 2300 to 0730 hours. Subjects were in bed during this period. When they awoke at 0730, a test agent was administered according to double-blind technique. Multiple Sleep Latency Tests (MSLT: 20-minute opportunities to fall asleep in bed while EEG and eye movements are recorded) were given at two-hour intervals throughout the day, and a 30-minute vigilance performance test was given at 1000 and 1600 hours. Subjects receiving cetirizine in doses of 5 to 20 mg did not differ from placebo controls in any objective or subjective measure of daytime alertness. Subjects receiving hydroxyzine were significantly more sedated and showed slower reaction times than the placebo control group for at least four hours after treatment. Self-rated feelings of sleepiness, impairment, and fatigue did not differ significantly between groups. This suggests that hydroxyzine subjects may not have been aware of their sleepiness and slower reaction times.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2892452

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  10 in total

Review 1.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Second-generation antihistamines: a comparative review.

Authors:  J W Slater; A D Zechnich; D G Haxby
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

Review 3.  Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

4.  Histamine H1 receptor antagonist cetirizine impairs working memory processing speed, but not episodic memory.

Authors:  P van Ruitenbeek; A Vermeeren; W J Riedel
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

5.  Induction of prolonged, continuous slow-wave sleep by blocking cerebral H₁ histamine receptors in rats.

Authors:  Masami Ikeda-Sagara; Tomoya Ozaki; Mohammad Shahid; Eri Morioka; Kazuma Wada; Kazuki Honda; Ayana Hori; Yuji Matsuya; Naoki Toyooka; Masayuki Ikeda
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

6.  Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine.

Authors:  N Okamura; K Yanai; M Higuchi; J Sakai; R Iwata; T Ido; H Sasaki; T Watanabe; M Itoh
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

7.  Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving.

Authors:  J G Ramaekers; M M Uiterwijk; J F O'Hanlon
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 8.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 9.  Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria.

Authors:  D M Campoli-Richards; M M Buckley; A Fitton
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 10.  Safety of antihistamines in children.

Authors:  A P Ten Eick; J L Blumer; M D Reed
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.